Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts

Springer Seminars in Immunopathology

Volumn 20, Issue 3-4, 1998, Pages 455-491

  O'Reilly, Richard J ^a   Small, Trudy N ^a   Papadupoulus, Esperanza ^a   Lucas, Kenneth ^a   Lacerda, Joao ^a   Koulova, Lidia ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELL IMMORTALIZATION; CELLULAR IMMUNITY; EPSTEIN BARR VIRUS; GENETIC DISORDER; HUMAN; LATENT VIRUS INFECTION; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS CELL TRANSFORMATION;

ACUTE DISEASE; ANIMALS; ANTIGENS, VIRAL; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CELL TRANSFORMATION, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOPROLIFERATIVE DISORDERS; RATS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; VIRAL PROTEINS; VIRUS LATENCY;

EID: 0031770175     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002810050047     Document Type: Article

References (228)

1. Altman JD, Moss PA, Goulder PR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen specific T lymphocytes. Science 274 : 94
2. Ambinder RF, Mann RB (1994) Detection and characterization of Epstein-Barr virus in clinical specimens. Am J Pathol 145 : 239
3. Andiman WA, et al (1985) Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS. Lancet II : 1390
4. Antin JH, Bierer BE, Smith BR, et al (1991) Selective depletion of bone marrow T-lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78 : 2139
5. Aversa F, Tabilio A, Terenzi A, et al (1994) Successful engraftment of T cell depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84 : 3948
6. Baichwal VR, Sugden B (1988) Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2 : 461
7. Baiocchi RA, Caligiuri MA (1994) Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in SCID/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci USA 91 : 5577
8. Baiocchi RA, Ross ME, Tan JC, et al (1995) Lymphogenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood 85 : 1063
9. Benjamin D, Knobloch TJ, Dayton MA (1992) Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 80 : 1289
10. Bonini C, Berzeletti S, Traversari C, Zappone E, Servida P, Rossini S, Bordignon C (1996) A pilot study of HSV-TK gene transfer into donor peripheral blood lymphocytes for controlled BVL after allo-BMT. Blood 88 [Suppl 1] : 487 a
11. Bonnefoy-Berard N, Flacher M, Revillard JP (1992) Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines. Blood 79 : 2164
12. + cell elimination regularly develops in uncloned human antiviral cell lines. J Immunol 142 : 252
13. Bourgeault I, Gomez A, Gomard E, et al (1991) Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T-lymphocytes. Clin Exp Immunol 84 : 501
14. Boyle TJ, Berend KR, DiMaio JM, Coles RE, Via DF, Lyerly HK (1993) Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery 114 : 218
15. Brenner MK, et al (1993) Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342 : 1134
16. Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB (1993) Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med 178 : 879
17. Buchsbaum RJ, Fabry JA, Lieberman J (1996) EBV-specific cytotoxic T lymphocytes protect against human EBV associated lymphoma in SCID mice. Immunol Lett 52 : 145
18. Burrows SR, Khanna R, Burrows JM, et al (1994) An alloresponse in humans is dominated by cytotoxic T-lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-vs-host disease. J Exp Med 179 : 1155
19. Burrows SR, Silins DL, Khanna R, Burrows JM, Rischmueller M, McCluskey J, Moss DJ (1997) Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bond peptide by T cells and its role in alloreactivity. Eur J Immunol 27 : 1726
20. + T cells in acute infectious mononucleosis. Nat Med 2 : 906
21. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 187 : 1395
22. Canfield CW, Hudnall SD, Colonna JO, et al (1992) Fulminant Epstein-Barr virus-associated post-transplant lymphoproliferative disorders following OKT3 therapy. Clin Transplant 6 : 1
23. Casper J, Camitta B, Truitt R, Baxter-Lowe LA, Bunin N, Lawton C, Murray K, Hunter J, Pietryga D, Garbrecht F, Keever Taylor C, Drobyski W, Horowitz M, Flomenberg N, Ash R (1995) Unrelated bone marrow transplants for children with leukemia or myelodysplasia. Blood 85 : 2354
24. Cen H, Breinig MC, Atchison RW, Ho M, McKnight JL (1993) Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, 13 and IR4. J Virol 65 : 976
25. Cen H, Wiliams PA, McWilliams HP, Breinig MC, Ho M, McKnight JL (1993) Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 81 : 1393
26. Chen BP, Lam V, Kraus EE, et al (1989) Restriction of Epstein-Barr virus-specific cytotoxic T cells by HLA-A,-B and -C molecules. Hum Immunol 26 : 137
27. Chen ML, Tsai CN, Liang CL, Shu CH, Huang CR, Sulitzeanu D, Liu ST, Chang YS (1992) Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7 : 2131
28. Chen WG, Chen YY, Bacchi CE, Alvarenga M, Weiss L M (1996) Genotyping of Epstein-Barr virus in Brazilian Burkitt's lymphoma and reactive lymphoid tissue. Type A with a high prevalence of deletions within the latent membrane protein gene. Am J Pathol 148 : 17
29. Cheung RK, Dosch HM (1991) The tyrosine kinase lck is critically involved in the growth transformation of human B-lymphocytes. J Biol Chem 266 : 8667
30. 90. Virology 193 : 700
31. Cohen JI, Wang F, Mannick J, et al (1989) Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA 86 : 9558
32. Cooper NR, Moore MD, Nemerow GR (1988) Immunobiology of CR2, the B lymphocyte receptor for EBV and C3D complement fragment. Annu Rev Immunol 6 : 85
33. Cordier M, Calender A, Billaud M, et al (1990) Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol 64 : 1002
34. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Joy JF (1991) Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 4 : 770
35. Dawson CW, Rickinson AB, Young LS (1990) Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 344 : 777
36. deCampos-Lima PO, Gavioli R, Zhang Q-J, et al (1993) HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science 260 : 98
37. Devergne O, Hatzivassiliou E, Izumi KM, et al (1996) Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol Cell Biol 16 : 7098
38. Dillner J, Kallin B (1988) The Epstein-Barr virus proteins. Adv Cancer Res 50 : 95-158
39. DiMaio JM, Van Trigt P, Gaynor JW, Davis RD, Coveney E, Clary BM, and Lyerly HK (1995) Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma. Circulation 92 [Suppl II] : 202-205
40. Durandy A, Emilie D, Peuchmaur M, et al (1994) Role of IL-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice. J Immunol 152 : 5361
41. Elliott SL, Pye SJ, Schmidt C, Cross SM, Silins SL, Misko IS (1997) Dominant cytotoxic T lymphocyte response to the immediate-early Trans-activator protein. BZLF1, in persistent type A or B Epstein-Barr virus infection. J Infect Dis 176 : 1068
42. Emanuel DJ, Lucas KG, Mallory GB Jr., Edwards-Brown MK, Pollok KE, Conrad PD, Robertson KA, Smith FO (1997) Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 63 : 1691
43. Emilie D, Coumbaras J, Raphael M, et al (1992) Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. Blood 80 : 498
44. Fahraeus B, Rymo L, Rhim JS, Klein G (1990) Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 345 : 447
45. Fiorentino DF, Bond MW, Mosmann TR (1989) Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170 : 2081
46. Frank D, Cesarman E, Liu YF, Michler RE, Knowles DM (1995) Post-transplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood 85 : 1396
47. Gahn TA, Schildkraut CL (1989) The Epstein-Barr virus origin of plasmic replication, oriP contains both the initiation and termination sites of DNA replication. Cell 58 : 527
48. Gavioli R, deCampos-Lima PO Kurilla MG, et al (1992) Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11 restricted cytotoxic T-lymphocytes: implications for downregulation of HLA-A11 in Burkitt's lymphoma. Proc Natl Acad Sci USA 89 : 5862
49. Gaviolo R, Kurilla MG, deCampos-Lima PO, et al (1993) Multiple HLA A11-restricted cytotoxic T lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol 67 : 1572
50. Golden HD, Chang RS, Prescott W, et al (1973) Leukocyte transforming agent prolonged excretion by patients with mononucleosis and excretion by normal individuals. J Infect Dis 127 : 471
51. Gratama JW, Zutter MM, Minarovits J, Oostserveer MA, Thomas, ED, Klein G, Ernberg I (1991) Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int J Cancer 47 : 188
52. Hale G, Waldmann H (1998) Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T cell-depleted marrow transplants. CAMPATH users. Blood 91 : 3079
53. Hale G, Cobbold S, Waldmann H (1988) T cell depletion with Campath-1 in allogeneic bone marrow transplantation. Transplantation 45 : 753
54. Hammerschmidt W, Sugden B (1989) Genetic analysis of immortalizing functions of Epstein-Barr virus in human B-lymphocytes. Nature 340 : 393
55. + T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. Arch Intern Med 155 : 1537
56. Hanto DW, Frizzera G, Gajl-Peczalska, et al (1985) Epstein-Barr virus, immunodeficiency and B-cell lymphoproliferation. Transplantation 39 : 461
57. Haynes BF, Schooley RT, Payling-Wright CR, et al (1979) Emergence of suppressor cells of immunoglobulin synthesis during acute Epstein-Barr virus-induced infectious mononucleosis. J Immunol 123 : 2095
58. Hayward S, Kieff E (1977) DNA of Epstein virus II. Comparison of the monoclonal weights of restriction endonuclease fragments of the DNA of Epstein-Barr virus strains and identification of end fragments of the B95-8 strain. J virol 23 : 421
59. Henderson S, Rowe M, Gregory C, et al (1991) Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65 : 1107
60. Henderson S, Huen D, Rowe M, et al (1993) Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death Proc Natl Acad Sci USA 90 : 8479
61. Henkl T, Ling PD, Hayward SD, Peterson MG (1994) Mediation of Epstein-Barr virus EBNA-2 transactivation by recombination signal-binding protein Jk. Science 262 : 92
62. Henle G, Henle W, Diehl V (1968) Relation of Burkitt's tumor associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA 59 : 94
63. Henle W, Henle G, Horowitz CA (1974) Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol 5 : 551
64. Heslop HE, Rooney CM (1997) Adoptive cellular immunotherapy for EBV lymphoproliferative diseases. Immunol Rev 157 : 217
65. Heslop HE, Brenner MK, Rooney CM (1994) Donor T cells to treat EBV-associated lymphoma. N Engl J Med 331 : 679
66. Heslop HE, Ng CYC, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2 : 551
67. Heslop HE, Smith CA, Ng C, Loftin SK, Sizbey J, Krance RA, Brenner MK, Rooney CM (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of genemodified virus-specific T lymphocytes. Nat Med 2 : 551
68. Ho M (1995) Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Transplantat Proc 27 [Suppl 5]: 38-40
69. Ho M, Jaffe R, Miller G, et al (1988) The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 45 : 719
70. Hu L, Chen F, Zheng F, Ernberg I, Cao S, Christenson B, Klein G, Winberg G (1993) Clonability and tumorigenicity of human epithelial cells expressing the EBV-encoded membrane protein LMP1. Oncogene 8 : 1575
71. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, Winberg G (1991) Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngcal carcinoma. J Gen Virol 72 : 2399
72. Izumi KM, Kaye KM, Kieff E (1997) The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci USA 94 : 1447
73. Jarriault S, Brou C, Logeat F, Schroeter E, Kopan R, Israel A (1995) Signalling downstream of activated notch. Nature 377 : 355
74. Jeang KT, Hayward SD (1983) Organization of the Epstein-Barr virus DNA molecule. III. Location of the P3HR-1 deletion junction and characterization of the Not1 repeat units that form part of the template for an abundant 12-O-tetradecanoylphorbol-13-acetate-induced mRNA transcript. J Virol 48 : 135
75. Jurgen W, Schirrmacher V, Mosier D (1995) Induction of CD44 expression by the Epstein-Barr-virus latent membrane protein LMP1 is associated with lymphoma dissemination. Int J Cancer 61 : 363
76. Kaminski E, Hows J, Man S, et al (1989) Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation 48 : 608
77. Kaplan LD, Abrams DI, Feigal E, et al (1989) AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 261 : 719
78. Kaye KM, Izumi KM, Kieff E (1993) Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 90 : 9150
79. Kaye KM, Devergne O, Harada JN, et al (1996) Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 93 : 11085
80. Kernan NA, Collins NH, Juliano L, et al (1986) Clonable T-Lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft vs. host disease. Blood 68 : 770
81. Kerr BM, Lear AL, Rowe M, Croom-Carter D, Young LS, Rookes SM, Gallimore PH, Rickinson AB (1992) Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 187 : 189
82. Khanna R, Burrows SR, Kurilla MG, et al (1992) Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 176 : 169
83. Khanna R, Burrows SR, Steigerwald-Mullen PM, Thomson SA, Kurilla MG, Moss DJ (1995) Isolation of cytotoxic T-lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology 214 : 633
84. Khanna R, Burrows SR, Moss DJ, Silins SL (1996) Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2 A: implications. J Virol 70 : 5357
85. Khanna R, Burrows SR, Neisig A, Meefjes J, Moss DJ, Silins DL (1997) Hierarchy of Epstein-Barr virus-specific cytotoxic T cell responses in individuals carrying different subtypes of an HLA-allele: implications for epitope-based antiviral vaccines. J Virol 71 : 7429
86. Khanna R, Busson P, Burrows SR, Raffoux C, Moss DJ, Nicholls JM, Cooper L (1998) Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T cell epitopes by NPC cells. Cancer Res 58 : 310
87. Kieff E, Liebowitz D (1990) Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Channock RM, et al (eds) Virology, 2nd edn. Raven Press, New York, pp 1889-1920
88. Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeld M (1996) Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 88 : 242
89. Klein C, Rothenberger S, Niemeyer C, Bachmann E, Odermatt B, Bohm N, Brandis M, Knecht H (1995) EBV-associated lymphoproliferative syndrome with a distinct 69 base-pair deletion in the LMP-1 oncogene. Br J Haematol 91 : 938
90. Klein E, Klein G, Levine PH (1981) Immunological control of human lymphoma: discussion. Cancer Res 41 : 4210
91. Knowles DM, Cesarman E, Chadbum A, et al (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85 : 552
92. Kusunoki Y, Huang H, Fukuda Y, et al (1993) A positive correlation between the precursor frequency of cytotoxic lymphocytes to autologous Epstein-Barr virus-transformed B cells and antibody titer level against Epstein-Barr virus-associated nuclear antigen in healthy seropositive individuals. Microbiol Immunol 37 : 461
93. Kuzushima K, Yamamoto M, Kimura H, Ando Y, Kudo T, Tsuge I, Morishi T (1996) Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 103 : 192
94. Lacerda JF, Ladanyi M, Jagiello C, O'Reilly RJ (1996) Administration of rabbit anti-asialo GM1 anti-serum facilitates the development of human Epstein-Barr virus-induced lymphoproliferations in xenografted C.B-17 SCID/scid mice. Transplantation 61 : 492
95. Lacerda JF, Ladanyi M, Louie DC, Jagiello C, Fernandez JM, Papadopoulos EB, O'Reilly RJ (1996) Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B-cell lymphoproliferations in xenografted C.B-17scid/scid mice. J Exp Med 183 : 1215
96. Lee SP, Thomas WA, Murray RJ, Rhanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB (1993) HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 67 : 7428
97. Lee SP, Morgan S, Skinner J, Thomas WA, Jones SR, Surron, Khanna R, Whittle HC, Rickinson AB (1995) Epstein-Barr virus isolated with the major HLA B35.01-restricted cytotoxic T-lymphocyte epitope are prevalent in a highly B35.01-positive African population. Eur J Immunol 25 : 102
98. Lee SP, Thomas WA, Blake NW, Rickinson AB (1996) Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2. Eur J Immunol 26 : 1875
99. Levine AM (1987) Non-Hodgkin's lymphomas and other malignancies in the acquired immune deficiency syndrome. Semin Oncol 14 : 34
100. Levitskaya J, Coram M, Levitsky V, et al (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375 : 685
101. Levitsky V, Zhang Q-J, Levitskaya J, Maaucci MG (1996) The life span of major histocompatibility complex-peptide complexes influences the efficienty of presentation and immunogenicity of two class I restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. J Exp Med 183 : 915
102. Levitsky V, Zhang QJ, Levitskaya J, Kurilla MG, Masucci MG (1997) Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from MHC class I:peptide complexes. J Immunol 159 : 5383
103. Liebowitz D (1996) Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 338 : 1413
104. Liebowitz D, Mannick J, Takada K, Kieff E (1992) Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. J Virol 66 : 4612
105. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ (1996) The development of cellular immunity to Epstein-Barr virus following allogeneic bone marrow transplantation. Blood 87 : 2594
106. Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornella KG, Robertson KA, Lee CH, Emanuel DJ (1998) Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 91 : 3654
107. Mackinnon S, Papadopoulos EP, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspine H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia following bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86 : 1261
108. Mannick JB, Cohen JI, Birkenbach M, et al (1991) The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol 65 : 6826
109. Martin PJ, Shulman HM, Schubach WH, et al (1984) Fatal Epstein-Barr virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T cell antibody. Ann Intern Med 101 : 310
110. Masood R, Zhang Y, Bond MW, et al (1995) Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 85 : 3423
111. Masucci MG, Bejarano MT, Masucci G, et al (1981) Large granular lymphocytosis inhibit the growth of autologous Epstein-Barr virus-infected B cells. Cell Immunol 127 : 293
112. Mavilio F, Ferrari G, Rossini S, Nobili N, Bonini C, Casorati G, Traversari C, Bordignon C (1994) Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 83 : 1
113. Meuer SC, Hodgdon JC, Cooper DA, et al (1983) Human cytotoxic T cell clones directed at autologous virus-transformed targets: further evidence for linkage of genetic restriction to T4 and T8 surface glycoproteins. J Immunol 131 : 186
114. Miller G (1990) Epstein-Barr virus: biology, pathogencsis and medical aspects. In: Fields BN, Knipe DM, (eds.) Virology. Raven Press, New York 1921-1958
115. Miller G (1990) The switch between latency and replication of Epstein-Barr virus. J Infect Dis 161 : 833
116. Miller G, Niederman JC, Andrews LL (1973) Prolonged oropharyngeal excretion of Epstein-Barr virus after infectious mononucleosis. N Engl J Med 288 : 229
117. Misko IS, Moss DJ, Pope JH (1980) HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc Natl Acad Sci USA 77 : 4247
118. Misko IS, Pope JH, Hutter R, et al (1984) HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T cell colonies. Int J Cancer 33 : 239
119. Miyazaki I, Cheung RK, Dosch HM (1993) Viral interleukin 10 is critical for the induction of B cell growth transformation by Epstein-Barr virus. J Exp Med 178 : 439
120. Moorthy RK, Thorley-Lawson DA (1993) All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol 67 : 1638
121. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80 : 389
122. Moss DJ, Rickinson AB and Pope, JH (1978) Long-term T cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer 22 : 662
123. Murray BM, Venuto RC, Kohli RK, et al (1992) Fatal lymphoma in association with OKT3 antibody therapy diagnosed by allograft biopsy. Clin Transplant 6 : 35
124. Murray PG, Swinner LJ, Constandinou CM, Pyle JM, Carr TJ, Hardwick JM, Ambinder RF (1996) BCL-2 but not its Epstein-Barr virus-encoded homologue. BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 87 : 706
125. Murray RJ, Kurilla MG, Brooks JM, et al (1992) Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 176 : 157
126. Nadal D, Albini B, Schlapfer E, Bernstein JM, Ogra PL (1992) Role of Epstein-Barr virus and interleukin 6 in the development of lymphomas of human origin in SCID mice engrafted with human tonsillar mononuclear cells. J Gen Virol 73 : 113
127. Nalesnik MA, Jaffe R, Starzl TE, et al (1988) The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine - A prednisone immunosuppression. Am J Pathol 133 : 173
128. Nalesnik MA, Rao AS, Furukawa H, Pham S, Zeevi A, Fung JJ, Klein G, Gritsch HA, Elder E, Whiteside TL, Starzl TE (1997) Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 63 : 1200
129. Opelz G, Henderson R (1993) Incidence of non-Hodgkin's lymphoma in kidney and heart transplant recipients. Lancet 342 : 1514
130. O'Reilly RJ, Lacerda JF, Lucas KG, Rosenfield, NS, Small TN, Papadopoulos EB (1996) Adoptive cell therapy with donor lymphocytes for EBV associated lymphomas developing after allogeneic marrow transplants. In: Devita V, Hellman S, Rosenberg S (eds) Important advances in oncology 1996, Philadelphia, Lippincott-Raven Pubushers, pp 149-166
131. Papadopoulos EB, Ladanyi M, Emanuel D, et al (1994) Infusions of donor leukocytes as treatment of Epstein-Barr virus associated lymphoproliferative disorders complicating allogeneic marrow transplantation. N Engl J Med 330 : 1185
132. Papadopoulos EB, Small TN, Ladanvi M, Boulad F, Castro-Malaspina H, Childs B, Kernan N, Mackinnon S, Szabolcs P, Young J, O'Reilly RJ (1996) Current results of donor leukocyte infusions (DLI) for treatment of Epstein-Barr virus associated lymphoproliferative disorders (EBV LPD) following related and unrelated T cell depleted bone marrow transplant (TCD BMT) [Abstract]. Blood 88 : 681 a
133. Pearson GR, Luka J, Petti L, et al (1987) Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 160 : 151
134. Penn I (1984) Allograft transplant cancer registry. In: Purtilo DT (ed.) Immune deficiency and cancer: Epstein-Barr virus and lymphoproliferative malignancies. Plenum Press New York, pp 281
135. Penn I (1987) Neoplastic consequences of transplantation and chemotherapy. Cancer Detect Prev [Supp I] : 149
136. Piccio GR, Kobayashi R, Kirven M, et al (1992) Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. Cancer Res 52 : 2468
137. Porter D, Collins R, Mick R, Kernan N, Giralt S, Flowers M, Casper J, Drobyski W, Leahey A, Parker P, Bates B, King R, Antin J (1997) Unrelated donor leukocyte infusions (U-DLI) to treat relapse or EBV-lymphoproliferative disease (EBV-LPD) after unrelated donor bone marrow transplantation (BMT). Blood 90 : 590 a
138. Porter DL, Orloff GJ, Antin JH (1994) Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant. Transplant Sci 4 : 12
139. Prasad VK, Kernan NA, Heller G, O'Reilly RJ, Yang SY (1997) DNA typing for HLA-A and -B identifies disparities between patients and unrelated donors matched by HLA-A and -B serology and DRB1. Blood 90 : 562 a
140. Pritchett R, Pendersen M, Kieff E (1976) Complexities of EBV homologous in continuous lymphoblastoid cell lines. Virology 74 : 227-231
141. Purtilo DT, Yang JPS, Cassel CK, et al (1975) X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1 : 935
142. Ralph PI, Nakoinz JA, Sampson S, et al (1992) 11-10 T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 148 : 808
143. Randhawa PS, Yousem SA, Paradis IL, et al (1989) The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients. Am J Clin Pathol 92 : 177
144. Randhawa PS, Whiteside TL, Zeevi A, Elder EM, Rao AS, Demetris AJ, Weng X, Valdivia LA, Rakela J, Nalesnik MA (1988) Effects of immunotherapy on experimental immunodeficiency-related lymphoproliferative disease. Transplantation 65 : 264
145. Rawlins DR, Milman G, Haward SD, et al (1985) Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 42 : 859
146. Rea D, Fourcade C, Leblond V, et al (1994) Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation 58 : 317
147. + cytotoxic T cells against Epstein-Barr virus-immortalized B-cell tumors in SCID mice. Transplantation 58 : 629
148. Rickinson AB, Kieff E (1996) Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, (eds) Fields Virology. Lippincott-Raven, Philadelphia pp 2397-2446
149. Rickinson AB, Moss DJ, Pope JH (1979) Long-term T cell immunity to Epstein-Barr virus in man. II. Components necessary for regression in virus infected leukocyte cultures. Int J Cancer 23 : 610
150. Rickinson AB, Wallace LE, Epstein MA (1980) HLA-restricted T cell recognition of Epstein-Barr virus-infected B cells. Nature 283 : 865
151. Rickinson AB, Moss DJ, Wallace LE, et al (1981) Long-term T cell-mediated immunity to Epstein-Barr virus. Cancer Res 41 : 4216
152. Rickinson AB, Young LS, Rowe M (1987) Influence of the Epstein-Barr virus nuclear antigen EBNA-2 on the growth phenotype of virus-transformed B cells. J Virol 61 : 1310
153. Rickinson AG, Lee SP, Steven NM (1998) Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 8 : 492
154. Riddell SR, Watanabe KS, Goodrich JM, et al (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257 : 238
155. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds TC, Corey L, Greenberg PD (1996) T cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2 : 216
156. Riddler SA, Breinig MC, McKnight JLC (1994) Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 84 : 972
157. Robertson ES, Lin J, Kieff, E (1996) The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJκ: J Virol 70 : 3068
158. Rocchi GA, De Felici A, Ragona G, et al (1977) Quantitative evaluation of Epstein-Barr virus infected mononuclear peripheral blood leukocytes in infectious mononucleosis. N Engl J Med 296 : 132
159. Rogers RP, Strominger JL, Speck SH (1992) Epstein-Barr virus B-lymphocytes: viral gene expression and function in latency. Adv Cancer Res 58 : 1
160. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE (1995) Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 89 : 98
161. Rooney CM, Smith CA, NG CY, et al (1995) Use of gene-modified virus-specific T-lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345 : 9
162. Rowe M, Young LS, Crocker J, et al (1991) Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 173 : 147
163. Sadelain M, Mulligan RC (1994) Efficient retroviral-mediated gene transfer into murine primary lymphocytes. Eighth International Immunology Congress [abstract]. Blood 83 : 001
164. Santamaria P, Reinsmoen NL, Lindstrom AL, Boyce-Jacino MT, Barbosa JJ, Faras AJ, McGlave PB, Rich SS (1994) Frequent HLA class I and DP sequence mismatches in serologically (HLA-A, HLA-B, HLA-DR) and molecularly (HLA-DRB1, HLA-DQA1, HLA-DQB1) HLA-identical unrelated bone marrow transplant pairs. Blood 83 : 280
165. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C (1994) Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 83 : 2715
166. Scala G, et al (1990) Expression of an exogenous inlerleukin 6 gene in human Epstein-Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med 172 : 61
167. Scheinfeld AG, Nador RG, Cesarman E, Chadhum A, Knowles DM (1997) Epstein-Barr virus latent membrane protein-1 oncogene deletion in post-transplantation lymphoproliferative disorders. Am J Pathol 151 : 805
168. Schendel DJ, Reinhardt C, Nelson PJ, et al (1992) Cytotoxic T-Lymphocytes show HLA-C-restricted recognition of EBV-hearing cells and allorecognition of HLA class I molecules presenting self-peptides. J Immunol 149 : 2406
169. Seeley J, Svedmyr OLA, Weiland GK, et al (1981) Epstein-Barr virus selective T cells in infectious mononucleosis are not restricted to HLA-A and B antigens. J Immunol 81 : 1271
170. Serraino D, Salamina G, Franceschi S, et al (1992) The epidemiology of AIDS-associated non-Hodgkin's lymphoma in the World Health Organization European Region. Br J Cancer 66 : 912
171. Servida P, Rossini S, Traversari C, et al (1993) Gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in a patient affected by EBV-induced lymphoma. Blood 82 : 214a
172. Shapiro RS, McClain K, Frizzera G, et al (1988) Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 71 : 1234
173. Shibata D, Weiss LM, Nathwani BN, Brynes RK, Levine AM (1991) Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma. Blood 77 : 1527
174. Silins SL, Sculley TB (1995) Burkitt's lymphoma cells are resistant to programmed cell death in the presence of the Epstein-Barr virus latent antigen DBNA-4. Int J Cancer 60 : 65
175. + Hodgkin's disease. Blood 89 : 1978
176. Sixbey JW, Nedrud JG, Raab-Traub N, et al (1984) Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 310 : 1225
177. Skinner JC, Gilbert EF, Hong R, et al (1988) B cell lymphoproliferative disorders following T cell depleted allogeneic bone marrow transplantation. Am J Pediatr Hematol/Oncol 10 : 112
178. Small TN, Flomenberg N, Black P, O'Reilly RJ, Kernan NA (1996) Comparison of immune reconstitution following T cell depleted bone marrow transplantation from related versus unrelated donors. [Abstract] Blood 78 : 226a
179. Small TN, Avigan D, Dupont B, Smith K, Black P, Heller G, Polyak T, O'Reilly RJ (1997) Immune reconstitution following T cell depleted bone marrow transplantation: effect of age and post-transplant graft rejection prophylaxis. Biol Blood Marrow Transplant 2 : 65
180. Smir BN, Hauke RJ, Bierman PJ, Gross TG, d'Amore F, Anderson JR, Greiner TC (1996) Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders. Lab Invest 75 : 575
181. Steven N, Leese AM, Annels NE, Lee SP, Rickinson AB (1996) Epitope focusing in the primary cytotoxic T cells response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med 184 : 1801
182. Steven N, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB (1997) Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 185 : 1605
183. Stuber G, Dillner J, Modrow S, Wolf H, Szekley L, Klein G, Klein E (1995) HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay: low proportion of binding motifs for several HLA class I alleles in EBNA-1. Int Immunol 7 : 653
184. Sugden B, Warren N (1989) A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 63 : 2644
185. Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD, Lotze MT (1995) Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 182 : 477
186. Svedmyr E, Jondal M (1975) Cytotoxic effector cells specific for B cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci USA 72 : 1622
187. Swinnen LJ, Constanzo-Nordin MR, Fisher SG, et al (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 323 : 1723
188. Szekely L, Selivanova G, Magnusson KP, et al (1993) EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 90 : 5455
189. Taga K and Tosato G (1992) 11-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 148 : 3133
190. Tamaki H, Beaulieu BL, Somasundaran M, Sullivan JL (1995) Major histocompatibility complex classI-restricted cytotoxic T-lymphocyte responses to Epstein-Barr virus in children. J Infect Dis 172 : 739
191. Tanaka Y, Sugamura K, Hinuma Y (1982) Heterogeneity of allogeneic restriction of human cytotoxic T cell clones specific for Epstein-Barr virus. J Immunol 128 : 1241
192. Tanner J, Tosato G (1991) Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Inves 88 : 239
193. Thomas JA, Hotchin NA, Allday MJ, Amlot P, Rose M, Yacoub M, Crawford DH (1990) Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 49 : 944
194. Thomas JA, Allday MJ, Crawford DH (1991) Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res 57 : 329
195. Thorley-Lawson DA, Chess L, Strominger JL (1977) Suppression of Epstein-Barr virus infection. A new role for the adult human T lymphocyte. J Exp Med 146 : 494
196. Tomkinson B, Kieff E (1992) nUse of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation. J Virol 66 : 2893
197. Tomkinson BE, Maziarz R, Sullivan JL (1989) Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol 143 : 660
198. Tosato G (1987) The Epstein-Barr virus and the immune system. Adv Cancer Res 49 : 75
199. Tosato G, Blaese RM (1985) Epstein-Barr virus infection and immunoregulation in man. Adv Immunol 37 : 99
200. Tosato G, Magrath I, Koski I, et al (1979) Activation of suppressor T cells during Epstein-Barr virus-induced infectious mononucleosis. N Engl J Med 301 : 1133
201. Tosato G, Steinberg AD, Yarchoan R, et al (1984) Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest 73 : 1789
202. Tosato G, Straus S, Henle W, et al (1985) Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis) J Immunol 134 : 3082
203. Tosato G, Yarchoan R, Blaese RM (1985) Relationship between immunoglobulin production and immortalization by Epstein-Barr virus. J Immunol 135 : 959
204. Trigg ML, Billing R, Sondel PM, Exten R, Hong R, Bozdech MJ, Horowitz SD, Finlay JL, Moen R, Longo W, et al (1985) Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants. Cancer Treat Rep 69 : 377
205. Trivedi P, Winberg G, Klein G (1997) Differential immunogenicity of Epstein-Barr virus (EBV) encoded growth transformation-associated antigens in a murine model system. Eur J Cancer 33 : 912
206. Viera P, Waal-Malefyt R de, Dang M-N, et al (1991) Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRF1. Proc Natl Acad Sci USA 88 : 1172
207. Walker RC, Marshal WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, McGregor CGA, Paya CV (1995) Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 20 : 1346
208. Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, Daly RC, McGregor CG (1995) Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 14 : 214
209. Wallace LE, Rickinson AB, Rowe M, et al (1982) Epstein-Barr virus-specific cytotoxic T cell clones restricted through a single HLA antigen. Nature 297 : 413
210. Waller EK, Ziemianska M, Bangs CD, Cleary M, Weissman I, Kamel OW (1993) Characterization of posttransplant lymphomas that express T cell-associated markers: immunophenotypes, molecular genetics, cytogenetics, and heterotransplantation in severe combined immunodeficient mice. Blood 82 : 247
211. Walter EA, Greenberg PD, Gilbert MJ, et al (1995) Reconstitution of cellular immunity against CMV in recipients of allogeneic bone marrow by adoptive transfer of T cell clones from the donor. N Engl J Med 333 : 1038
212. Wang D, Liebowitz D, Kieff E (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43 : 831
213. Wang D, Liebowitz D, Wang F, et al (1988) Epstein-Barr virus latent infection membrane protein (LMP) alters human B lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 62 : 4173
214. Wang F, Blaese RM, Zoon KC, et al (1987) Suppressor T cell clones from patients with acute Epstein-Barr virus-induced infectious mononucleosis. J Clin Invest 79 : 7
215. Wang F, Gregory CD, Rowe M (1987) Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci USA 84 : 3452
216. Wang F, Gregory C, Sample C, et al (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B-lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64 : 2309
217. Weintraub I and Warnke RA (1982) Lymphoma in cardiac allograft recipients. Clinical and histological features and immunological phenotype. Transplantation 33 : 347
218. + virus-specific cytotoxic T cells which recognize Epstein-Barr virus lytic antigen BHRF1. Virology. 219 : 489
219. Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ (1990) Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 61 : 1315
220. Wood BL, Sabath D, Broudy VC, Raghu G (1996) The recipient origin of posttransplant lymphoproliferative disorders in pulmonary transplant patients. A report of three cases. Cancer 78 : 2223
221. Wrightham MN, Stewart JP, Janjua NJ, Pepper SDV, Sample C, Rooney CM, Arrand JR (1995) Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1. Virology 208 : 521
222. Yang SY, Milford E, Hammerling U, Dupont B (1987) Description of the reference panel of B-lymphoblastoid cell lines for factors of the HLA system: the B-cell line panel designed for the tenth international histocompatibility workshop. In: Dupont B (ed) Immunobiology of HLA, vol 1 Springer, New York pp 11-19
223. Yao QY, Rickinson AB, Epstein MA (1985) A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 35 : 35
224. Yates JL, Warren N, Sugden B (1985) Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313 : 812
225. Young L, Alfieri C, Hennessy K, et al (1989) Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321 : 1080
226. Zhang Q, Gursch D, Kenney S (1994) Functional and physical interaction between p53 and ZALF1: implications for Epstein-Barr virus latency. Mol Cell Biol 14 : 1929
227. Ziegler JL, Beekstead JA, Volberding PA, et al (1984) Non-Hodgkin's lymphoma in 90 homosexual men. N Engl J Med 311 : 565
228. Zutter MM, Martin PJ, Sale GE, et al (1984) Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72 : 520